Şunu aradınız:: calcineurin (İngilizce - Danca)

calcineurin inhibitors, atc code:
calcineurinhæmmere, atc- kode:

contains the active substance pimecrolimus, a calcineurin inhibitor.
{(sær) navn} indeholder den aktive substans pimecrolimus, som er en calcineurinhæmmer.

protopic contains the active substance tacrolimus, a calcineurin inhibitor.
protopic indeholder den aktive substans tacrolimus, som er en calcinurinhæmmer.

tacrolimus is a macrolide immunosuppressant belonging to the pharmacological class of the calcineurin inhibitors.
tacrolimus er et immunosuppressivum af macrolid- typen, der farmakologisk tilhører klassen af calcineurin- hæmmere.

pimecrolimus is a calcineurin inhibitor approved as cream formulation at a 1% concentration.
pimecrolimus er en calcineurin- inhibitor, der er godkendt som cremeformulering med en koncentration på 1%.

renal function was not better in the treatment arms with de novo rapamune without a calcineurin inhibitor.
nyrefunktionen var ikke bedre i behandlingsarmene med de novo rapamune uden en calcineurinhæmmer.

pharmacotherapeutic group: immunosuppressants, calcineurin inhibitors, atc code: l04ad02 mechanism of action
farmakoterapeutisk klassifikation: immunsuppressiva, calcineurinhæmmere, atc-kode: l04ad02 virkningsmekanisme

the safety and efficacy of conversion from calcineurin inhibitors to rapamune in maintenance renal transplant patients have not been established.
sikkerhed og effekt ved skift fra calcineurin hæmmere til rapamune til nyretransplanterede patienter i vedligeholdelsesbehandling er ikke fastslået.

pimecrolimus binds with high affinity to macrophilin-12 and inhibits the calcium-dependent phosphatase calcineurin.
pimecrolimus bindes med høj affinitet til macrofilin- 12 og hæmmer den calciumafhængige fosfatase calcineurin.

prolonged systemic exposure to intense immunosuppression in transplant patients following systemic administration of calcineurin inhibitors has been associated with an increased risk of developing lymphomas and skin malignancies.
langvarig systemisk eksponering for intens immunosuppression hos transplanterede patienter efter systemisk administration af calcineurin- inhibitorer er blevet associeret med en øget risiko for udvikling af lymfomer og hudmaligniteter.

in transplant patients, prolonged systemic exposure to intense immunosuppression following systemic administration of calcineurin inhibitors has been associated with an increased risk of developing lymphomas and skin malignancies.
hos transplantationspatienter er langvarig systemisk og intens immunosuppression efter systemisk administration af calcinurinhæmmere associeret med en øget risiko for udvikling af lymfomer og hudmaligniteter.

the concomitant use of sirolimus with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced hus/ ttp/ tma.
samtidig brug af sirolimus og calcineurinhæmmer øger muligvis risikoen for calcineurinhæmmer - induceret hus/ ttp/ tma.

the concomitant use of rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced haemolytic uraemic syndrome/ thrombotic thrombocytopenic purpura/ thrombotic microangiopathy (hus/ ttp/ tma).
samtidig brug af rapamune og calcineurinhæmmer øger muligvis risikoen for calcineurinhæmmer - induceret hæmolytisk uræmisk syndrom/ trombotisk trombocytopenisk purpura/ trombotisk mikroangiopati (hus/ ttp/ tma).